Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2006

View Archived Issues

Inhibiting cathepsin K: effective blockade of bone resorption. Part II: preclinical activity

SBIR contract supports dendrimer work in epithelial ovarian cancer

Immunicon and MolMed enter research and laboratory services agreements

S-44029, a novel ADAM inhibitor, blocks osteoclastogenesis in vivo

Long-term efficacy seen with teriflunomide in multiple sclerosis

Studies reveal effects of natalizumab in multiple sclerosis patients

Antibiotic candidate from Oragenics has novel mechanism of action

Sanofi pasteur and PDVI partner on dengue vaccine initiatives

A.P. Pharma licenses APF-530 to RHEI Pharmaceuticals in Greater China

CGC-11047 studied with chemotherapeutics in new phase Ib trial

DelSite and NCI team up on GelVac nasal delivery of HPV vaccines

Plexxikon and Servier collaborate to discover renin inhibitors

UCB and Biogen Idec collaborate on CDP-323 for MS

Enanta reports on its novel macrolide antibiotic candidate

Possible higher risk of cleft palate in babies exposed to Lamictal

Alkermes developing oral products for treatment of addiction

ADH-1 to be studied in combination with docetaxel, carboplatin or capecitabine

Plexxikon submits IND for targeted cancer therapeutic PLX-4032

CrystalGenomics describes new anti-MRSA candidate

SRI International to conduct preclinical testing of Taiwan Liposome's cancer drug

Kyowa Hakko licenses anticancer agent KW-2401 to Keryx

Starpharma to acquire Dendritic Nanotechnologies

Ozarelix improves clinical symptoms of BPH in phase II trial

Canadian approval for Tysabri in relapsing-remitting MS

Hematopoietic-stimulating properties of HE-3210

EGFR pharmDx kit approved for use with Vectibix

FDA approval for Procleix Ultrio Assay

New alpha1A receptor antagonists for BPH prepared and tested at Ranbaxy

New potential HIV treatments reported in recent patent literature

New antidiabetic agents imparted in recent patent literature

R&D highlights from the UBS Global Life Sciences Conference in New York: QLT

Preclinical activity of Ceragenix's Ceragenin compounds against infectious diseases reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...